{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:54:41Z","timestamp":1791561281158,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.leukres.2025.107642","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T01:18:05Z","timestamp":1736471885000},"page":"107642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["New treatments for adult T-cell leukemia\/lymphoma"],"prefix":"10.1016","volume":"149","author":[{"given":"Zachary D.","family":"Epstein-Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-7769","authenticated-orcid":false,"given":"Ashwath","family":"Gurumurthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6399-2006","authenticated-orcid":false,"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2025.107642_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1146\/annurev-immunol-042617-053222","article-title":"Human T cell leukemia virus type 1: persistence and pathogenesis","volume":"36","author":"Bangham","year":"2018","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.leukres.2025.107642_bib2","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1038\/s41467-021-25101-9","article-title":"Chronological genome and single-cell transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma","volume":"12","author":"Yamagishi","year":"2021","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.leukres.2025.107642_bib3","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107642_bib4","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-179304","article-title":"Efficacy and safety of Valemetostat monotherapy in patients with relapsed or refractory peripheral T-Cell lymphomas: primary results of the phase 2 VALENTINE-PTCL01 Study","volume":"142","author":"Horwitz","year":"2023","journal-title":"Blood"},{"issue":"8002","key":"10.1016\/j.leukres.2025.107642_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-024-07103-x","article-title":"Mechanisms of action and resistance in histone methylation-targeted therapy","volume":"627","author":"Yamagishi","year":"2024","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.leukres.2025.107642_bib6","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(15)00284-7","article-title":"Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study","volume":"3","author":"Ogura","year":"2016","journal-title":"Lancet Haematol."},{"issue":"34","key":"10.1016\/j.leukres.2025.107642_bib7","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2025.107642_bib8","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.6004\/jnccn.2020.0053","article-title":"NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021","volume":"18","author":"Horwitz","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"3","key":"10.1016\/j.leukres.2025.107642_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hon.3115","article-title":"Lenalidomide treatment for recurrent adult T-cell leukemia\/lymphoma after allogeneic hematopoietic cell transplantation","volume":"41","author":"Tanaka","year":"2023","journal-title":"Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2025.107642_bib10","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1111\/cas.15431","article-title":"Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia\/lymphoma: phase IIb results","volume":"113","author":"Utsunomiya","year":"2022","journal-title":"Cancer Sci."},{"issue":"ement 1","key":"10.1016\/j.leukres.2025.107642_bib11","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1182\/blood-2022-167888","article-title":"Safety and efficacy of belinostat trial with zidovudine plus interferon for HTLV-1 related adult T-cell leukemia-lymphoma: interim results","volume":"140","author":"Pongas","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2025.107642_bib12","first-page":"363","article-title":"Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma, Blood","volume":"134","author":"Wu","year":"2019","journal-title":"J. Am. Soc. Hematol."},{"key":"10.1016\/j.leukres.2025.107642_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.14300","article-title":"A new strategy for adult T-cell leukemia treatment targeting glycogen synthase kinase-3\u03b2","author":"Ishikawa","year":"2024","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2025.107642_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/15384047.2022.2088984","article-title":"Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3\u03b2) inhibitor, in refractory adult T-Cell leukemia\/lymphoma","volume":"23","author":"Hsu","year":"2022","journal-title":"Cancer Biol. Ther."},{"issue":"8","key":"10.1016\/j.leukres.2025.107642_bib15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2025.107642_bib16","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s11864-023-01111-1","article-title":"Treatment of adult T-cell leukemia\/lymphoma: established paradigms and emerging directions","volume":"24","author":"Stuver","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"issue":"28","key":"10.1016\/j.leukres.2025.107642_bib17","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","article-title":"Pretransplantation anti-CCR4 antibody Mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality","volume":"34","author":"Fuji","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2025.107642_bib18","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s12185-017-2270-9","article-title":"Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance","volume":"106","author":"Ishitsuka","year":"2017","journal-title":"Int J. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2025.107642_bib19","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3324\/haematol.2018.205096","article-title":"Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"104","author":"Phillips","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2025.107642_bib20","unstructured":"NCCN, T-Cell Lymphomas Version 4.2024 \u2014 May 28, 2024, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t-cell.pdf. (Accessed 7\/8\/2024 2024)."},{"key":"10.1016\/j.leukres.2025.107642_bib21","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.V130.Suppl_1.720.720","article-title":"Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas","volume":"130","author":"Kitadate","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2025.107642_bib22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2025.107642_bib23","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/bjh.18281","article-title":"Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma","volume":"198","author":"Shichijo","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2025.107642_bib24","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.21873\/anticanres.14527","article-title":"Mogamulizumab plus EPOCH therapy for patients with newly diagnosed aggressive adult T-cell leukemia\/lymphoma","volume":"40","author":"Jo","year":"2020","journal-title":"Anticancer Res."},{"key":"10.1016\/j.leukres.2025.107642_bib25","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1182\/blood-2021-151937","article-title":"CHOP plus sequential mogamulizumab as first-line therapy for untreated adult T-cell leukemia-lymphoma","volume":"138","author":"Tanimoto","year":"2021","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.leukres.2025.107642_bib26","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107642_bib27","article-title":"A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia\/lymphoma, American society","author":"Choi","year":"2023","journal-title":"Clin. Oncol."},{"issue":"26","key":"10.1016\/j.leukres.2025.107642_bib28","first-page":"3732","article-title":"Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma, Blood","volume":"139","author":"Beygi","year":"2022","journal-title":"J. Am. Soc. Hematol."},{"key":"10.1016\/j.leukres.2025.107642_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100601","article-title":"Risk of hepatitis B reactivation and cytomegalovirus related infections with Mogamulizumab: a retrospective study of international pharmacovigilance database","volume":"28","author":"Wang","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"10168","key":"10.1016\/j.leukres.2025.107642_bib30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.leukres.2025.107642_bib31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1440-1827.2007.02195.x","article-title":"Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases","volume":"58","author":"Karube","year":"2008","journal-title":"Pathol. Int."},{"issue":"8","key":"10.1016\/j.leukres.2025.107642_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100169","article-title":"A comprehensive study of the immunophenotype and its clinicopathologic significance in adult T-cell leukemia\/lymphoma","volume":"36","author":"Tamaki","year":"2023","journal-title":"Mod. Pathol."},{"issue":"ement 1","key":"10.1016\/j.leukres.2025.107642_bib33","article-title":"Final results of a multicenter pilot study evaluating Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukemia\/lymphoma","volume":"142","author":"Dittus","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2025.107642_bib34","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/oncolo\/oyac137","article-title":"Response to Brentuximab Vedotin by CD30 expression in Non-Hodgkin lymphoma","volume":"27","author":"Jagadeesh","year":"2022","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.leukres.2025.107642_bib35","doi-asserted-by":"crossref","DOI":"10.1097\/CAD.0000000000000895","article-title":"Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia","volume":"31","author":"Oka","year":"2020","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.leukres.2025.107642_bib36","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.HS9.0000843940.96598.e2","article-title":"S262: The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-CAS9\u2013engineered CAR T cells in patients with relapsed\/refractory (R\/R) T-cell malignancies","volume":"6","author":"Iyer","year":"2022","journal-title":"HemaSphere"},{"issue":"13","key":"10.1016\/j.leukres.2025.107642_bib37","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood.2023022204","article-title":"Antitumor efficacy and safety of unedited autologous CD5. CAR T cells in relapsed\/refractory mature T-cell lymphomas","volume":"143","author":"Hill","year":"2024","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.leukres.2025.107642_bib38","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1182\/blood-2022-162222","article-title":"Development of anti-CD3 chimeric antigen receptor (CAR)-T cells for allogeneic cell therapy of peripheral T-cell lymphoma (PTCL)","volume":"140","author":"Qian","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2025.107642_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"issue":"14","key":"10.1016\/j.leukres.2025.107642_bib40","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/bloodadvances.2022008327","article-title":"Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma","volume":"7","author":"Watanabe","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2025.107642_bib41","article-title":"The chemokine receptor CCR8 is a target of chimeric antigen T cells for treating T cell malignancies","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T13:31:44Z","timestamp":1740403904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625000025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":41,"alternative-id":["S0145212625000025"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107642","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New treatments for adult T-cell leukemia\/lymphoma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107642"}}